This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.

Start Date01 Jun 2025

Sponsor / Collaborator

VA Office of Research and Development

NCT06840470

/ Not yet recruitingPhase 4IIT

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

This study is being completed to determine if 8 weeks of treatment with imiquimod can shrink sebaceous hyperplasia.

Start Date01 Mar 2025

Sponsor / Collaborator

University of Michigan

NCT06686043

/ RecruitingPhase 2IIT

A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are:
Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone.
Participants will:
Receive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation.
Have blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit.
Take a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.

Start Date23 Aug 2024

Sponsor / Collaborator

Baylor College of Medicine

[+2]

100 Clinical Results associated with Imiquimod

100 Translational Medicine associated with Imiquimod

100 Patents (Medical) associated with Imiquimod

5,429

Literatures (Medical) associated with Imiquimod

01 Jun 2025·BIOMATERIALS

Ultrasound-triggered drug-loaded nanobubbles for enhanced T cell recruitment in cancer chemoimmunotherapy

Article

Author: Li, Xin ; Ling, Yi ; Dong, Li ; Deng, Jun ; Guo, Yanli ; Huang, Haiyun ; Liu, Deng ; Zhang, Jun ; Chen, Xuemei

Chemotherapy combined with immunotherapy is a highly promising approach for treating tumors. However, chemotherapeutic drugs often fail to accumulate effectively at the tumor site after systemic administration and they lack sufficient immunogenicity to activate adaptive immunity, making an effective T-cell immune response within the tumor microenvironment difficult to achieve. Here, this work developed drug-loaded nanobubbles (DTX-R837@NBs) that encapsulate the chemotherapy drug docetaxel and the immune adjuvant R837 via a thin-ﬁlm hydration method. Ultrasound-targeted nanobubble destruction promoted drug accumulation within tumor tissues and damaged tumor cells through the cavitation effect, inducing immunogenic cell death and releasing damage-associated molecular patterns to augment dendritic cell maturation. Notably, DTX-R837@NBs exhibited excellent contrast-enhanced ultrasound imaging capabilities, enabling the seamless integration of diagnosis and treatment. In combination with immune checkpoint blockade targeting programmed cell death protein 1 (PD-1), the generated immunological responses attacked residual tumor cells and ameliorated the immunosuppressive tumor microenvironment, inhibiting distant tumor growth and metastasis. Moreover, this strategy exhibited robust immune memory effects, effectively protecting the host and preventing tumor recurrence upon rechallenge. Overall, ultrasound-mediated DTX-R837@NBs combined with anti-PD-1 immune checkpoint blockade therapy exhibits robust antitumor efficiency, represent a promising strategy for overcoming immunotherapy resistance in cold tumors, and warrant further investigation for clinical translation.

01 Apr 2025·Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Randomized clinical trial of imiquimod compared with fludroxycortide in the treatment of actinic cheilitis

Article

Author: Spanemberg, Juliana Cassol ; Fumagalli, Maiara Jochims ; Cherubini, Karen ; Salum, Fernanda Gonçalves

OBJECTIVE:

Actinic cheilitis (AC) is a potentially malignant disorder of the lip vermillion. The study of effective therapeutic options is of the utmost importance to prevent the development of lip squamous cell carcinoma. This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.125 mg/g creams in the treatment of AC.

STUDY DESIGN:

A randomized controlled trial was conducted. Twenty-five participants of both genders, with a clinical diagnosis of AC, were divided into IM (n=13) and FC (n=12) groups. The treatment duration was six weeks for both groups. Participants were followed up by regular visits for clinical examination and photographic documentation.

RESULTS:

At the end of 180 days, the clinical outcomes were evaluated. In the IM group, there was a significant improvement in AC after 180 days of follow-up (P = .005). In the FC group, there was no significant improvement (P = .317). There was a significant difference between the groups in the clinical outcomes (P = .000).

CONCLUSION:

This study suggests that imiquimod may be a treatment option for AC in more advanced clinical cases, but local reactions should be expected. Conversely, fludroxycortide demonstrated no clinical efficacy, and therefore, should be avoided in AC cases presenting with leukoplakia.

01 Apr 2025·BIOMATERIALS

On-demand reprogramming of immunosuppressive microenvironment in tumor tissue via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immunotherapy using engineered gold nanoparticles for malignant tumor treatment

Article

Author: Liu, Tao ; Zhu, Zeren ; Chen, Xin ; Tang, Xiaoyu ; Mu, Wenyun ; Weng, Lin ; Zhang, Yanmin ; Liu, Jie ; Cheng, Yumeng ; Tang, Wenjun ; Zhu, Man ; Chen, Li

The frequent immune escape of tumor cells and fluctuating therapeutic efficiency vary with each individual are two critical issues for immunotherapy against malignant tumor. Herein, we fabricated an intelligent core-shell nanoparticle (SNAs@CCM_R) to significantly inhibit the PD-1/PD-L1 mediated immune escape by on-demand regulation of various oncogenic microRNAs and perform RNAs dependent photothermal-immunotherapy to achieve precise and efficient treatment meeting the individual requirements of specific patients by in situ generation of customized tumor-associated antigens. The SNAs@CCM_R consisted of antisense oligonucleotides grafted gold nanoparticles (SNAs) as core and TLR7 agonist imiquimod (R837) functionalized cancer cell membrane (CCM) as shell, in which the acid-labile Schiff base bond was used to connect the R837 and CCM. During therapy, the acid environment of tumor tissue cleaved the Schiff base to generate free R837 and SNAs@CCM. The SNAs@CCM further entered tumor cells via CCM mediated internalization, and then specifically hybridized with over-expressed miR-130a and miR-21, resulting in effective inhibition of the migration and PD-L1 expression of tumor cells to avoid their immune escape. Meanwhile, the RNAs capture also caused significant aggregation of SNAs, which immediately generated photothermal agents within tumor cells to perform highly selective photothermal therapy under NIR irradiation. These chain processes not only damaged the primary tumor, but also produced plenty of tumor-associated antigens, which matured the surrounding dendritic cells (DCs) and activated anti-tumor T cells along with the released R837, resulting in the enhanced immunotherapy with suppressive immune escape. Both in vivo and in vitro experiments demonstrated that our nanoparticles were able to inhibit primary tumor and its metastasis via multi-regulation of carcinogenic microRNAs and RNAs dependent photothermal-immune activations, which provided a promising strategy to reprogram the immunosuppressive microenvironment in tumor tissue for better malignant tumor therapy.

News (Medical) associated with Imiquimod

02 Jul 2024

·www.globenewswire.com

Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that George Warren, Ph.D., Principal Scientist at Artelo, Myles Osborn, Medicinal Chemist at Artelo, and Matthew Jones, Ph.D. candidate from the Laviolette laboratory at the University of Western Ontario, Canada, each presented results from research studies demonstrating the broad therapeutic potential of Fatty Acid Binding Protein 5 (FABP5) inhibition at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium. The ICRS Symposium is being held June 30 – July 5, 2024 in Salamanca, Spain. Targeting FABP5, a promising new approach to treat cancer, was featured in the presentation “Efficacy of ART26.12, a Novel Fatty Acid Binding Protein 5 Inhibitor, in an Orthotopic HCT-116-LUC Human Colon Cancer Model.” Myles Osborn discussed novel preclinical data showing a direct anti-tumoral effect of oral treatment with ART26.12. These data are also supportive of Artelo’s planned development of ART26.12 in chemotherapy-induced peripheral neuropathy, where ART26.12 may be able to aid in treatment of the underlying cancer, in addition to the debilitating effects of painful neuropathies. Beyond development for pain and cancer, ART26.12 has also shown the potential for therapeutic activity in dermatologic conditions. FABP5 was first identified in psoriatic lesions and there is evidence to suggest that upregulation of FABP5 contributes to the pathology of psoriasis. Regarding the data in his presentation, “A Novel Fatty Acid-binding Protein 5 Inhibitor Shows Efficacy in Preclinical Models of Psoriasis,” George Warren, Ph.D. commented, “We are pleased to share novel data showing that our lead FABP5 inhibitor, ART26.12, demonstrated compelling data in preclinical models of psoriasis. In this study, ART26.12 reduced the severity of histopathological markers of skin damage and reduced markers of oxidative stress, chemokines, cytokines, and keratinocyte proliferation, and increased antimicrobial peptides. Results were obtained using a standard imiquimod mouse model, which demonstrated ART26.12 had similar levels of activity as Sotyktu (deucravacitinib), an oral tyrosine kinase 2 inhibitor approved by the U.S. Food and Drug Administration in 2022 to treat psoriasis. Sales of Sotyktu may reach $4 billion by the end of the decade, according to Bristol Myers Squibb.” In addition to ART26.12, another one of Artelo’s FABP5 inhibitors was featured in a presentation entitled, “Inhibition of Fatty Acid Binding Protein 5 Prevents Stress-induced Anxiety and Depressive-Like Behavioral Symptoms and Reverses Stress-induced Inhibition of Hippocampal Neurogenesis” where Matthew Jones discussed new results from ongoing studies being conducted at the laboratory of Dr. Steven Laviolette. The data showed that Artelo’s FABP5 inhibitor SBFI103 improved depressive-like behaviors in rats after chronic unpredictable stress, associated with increases in markers of neurogenesis, a critical process in which newly formed neural cells are added to the existing neural network. “This new data supports our laboratory’s earlier work showing SBFI103 reduces anxiety and increased fear memory extinction. These studies implicate a role for the cannabinoid receptor 2 mediating the effects of FABP5 inhibition in the brain,” concluded Jones. “We are pleased to share the expanding evidence for the potential utility of inhibiting FABP5,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo. “These important scientific advances show that lipid modulation is a promising therapeutic strategy across multiple diseases where overactivity of the lipidome contributes to the pathology of the disease or where modulation of the lipidome leads to increased levels of analgesic and anxiolytic lipids. We are grateful for the opportunity to share our data and why we believe development of FABP5 inhibitors from our extensive library could have significant impact for a wide range of diseases. We expect to report on first-in-human trials with ART26.12 next year.” About ART26.12Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN). Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, and anxiety disorders. About the International Cannabinoid Research SocietyThe International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. The ICRS Symposium is being held June 30 – July 5, 2024 in Salamanca, Spain. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information and to view available publications, please visit https://artelobio.com/science/. Forward Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Drug ApprovalClinical Result

01 Jul 2024

·www.drugs.com

Few Patients With Positive Margins After Basal Cell Excision Have Recurrence

MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence, according to a study published online June 13 in Dermatology . Maria Daviti, M.D., from Aristotle University in Thessaloniki, Greece, and colleagues reported the real-life management of incompletely excised BCC in a tertiary referral center and compared recurrence rates according to management modality in a retrospective study. All BCCs with available histopathologic assay reporting at least one involved margin (lateral or deep) over a five-year period were identified. Patients were categorized into three groups: immediate re-excision (group 1; 26 patients); follow-up without any additional treatment (group 2; 40 patients); and treatment with adjuvant/complementary nonsurgical treatment (group 3; 18 patients). The researchers found that based on histopathological reports, 53.8 percent of 26 tumors in group 1 that were re-excised had residual tumor. After a mean follow-up of 17 months, a clinical recurrence occurred in 14 of 84 patients (16.7 percent), with a median of 14 months to recurrence. Recurrence developed in 25 percent of the patients without any additional treatment, compared with 11.1 percent of those receiving nonsurgical treatments. "Our study suggests that positive histopathologic margins after BCC excision result in a clinical recurrence only in a proportion of patients," the authors write. "This percentage is higher when no further treatment is applied and lower when the area is re-excised or treated with imiquimod alone or combined with cryotherapy." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

29 Dec 2023

·synapse.patsnap.com

What are TLR7 agonists and how do you quickly get the latest development progress?

TLR7, or Toll-like receptor 7, is a crucial component of the innate immune system in humans. It is a pattern recognition receptor that recognizes viral RNA and triggers an immune response against viral infections. TLR7 is primarily expressed in immune cells such as dendritic cells and macrophages. Upon activation, TLR7 initiates a signaling cascade that leads to the production of pro-inflammatory cytokines and type I interferons, which are essential for antiviral defense. Understanding the role of TLR7 in the human body is vital for developing therapeutic interventions targeting viral infections and autoimmune diseases. The analysis of target TLR7 from various perspectives provides valuable insights into the current competitive landscape and future development. Companies such as Roche Holding AG, Viatris Inc., and Bausch Health Cos., Inc. have shown significant progress in the development of drugs targeting TLR7. Indications such as hepatitis B, various types of cancer, and infectious diseases have received attention in the development of drugs under target TLR7. The presence of small molecule drugs and monoclonal antibodies indicates intense competition, while the involvement of biosimilar research and development institutions should be monitored. The United States, European Union, and China are leading in terms of research and development activities for target TLR7. Overall, the analysis suggests a promising future for the development of drugs targeting TLR7, with potential breakthroughs in the treatment of various diseases. How do they work?TLR7 agonists are a type of compounds that activate Toll-like receptor 7 (TLR7) in the immune system. Toll-like receptors are proteins that play a crucial role in recognizing and responding to pathogens, such as viruses and bacteria. TLR7 specifically recognizes viral RNA, triggering an immune response to eliminate the invading virus. TLR7 agonists are designed to mimic viral RNA and activate TLR7, thereby stimulating the immune system to mount a robust antiviral response. They can enhance the production of cytokines, such as interferons and pro-inflammatory molecules, which help in the elimination of viral infections. Additionally, TLR7 agonists can promote the maturation and activation of immune cells, such as dendritic cells, which are essential for initiating and coordinating immune responses. From a biomedical perspective, TLR7 agonists have gained attention as potential therapeutic agents for viral infections, including respiratory viruses like influenza and SARS-CoV-2 (the virus causing COVID-19). By activating TLR7, these agonists can boost the immune response against the virus, potentially reducing viral replication and improving clinical outcomes. It is important to note that TLR7 agonists are still under investigation and development, and their safety and efficacy need to be thoroughly evaluated through preclinical and clinical studies before they can be used as approved treatments. List of TLR7 AgonistsThe currently marketed TLR7 agonists include: ImiquimodAfimetoranAL-034BDB-001(Seven and Eight Biopharm)BDC-1001BNT-411DSP-0509EnpatoranNKTR-262ResiquimodFor more information, please click on the image below. What are TLR7 agonists used for?TLR7 agonists are primarily being studied for their role in immunotherapy, specifically in oncological indications. For more information, please click on the image below to log in and search. How to obtain the latest development progress of TLR7 agonists?In the Synapse database, you can keep abreast of the latest research and development advances of TLR7 agonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Imiquimod

External Link

KEGG	Wiki	ATC	Drug Bank
D02500	Imiquimod	D06BB10	DB00724

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Warts	United States	Bausch Health US LLC	24 Mar 2011
Warts	United States	Graceway Pharmaceuticals LLC	24 Mar 2011
Basal Cell Carcinoma	United States	Bausch Health US LLC	14 Jul 2004
Actinic Keratosis	European Union	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	Iceland	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	Liechtenstein	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Actinic Keratosis	Norway	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	European Union	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	Iceland	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	Liechtenstein	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Superficial basal cell carcinoma	Norway	Viatris Healthcare (Pty) Ltd.	18 Sep 1998
Condylomata Acuminata	United States	Bausch Health US LLC	27 Feb 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cervical Intraepithelial Neoplasia	Phase 3	Netherlands	Meda Pharma GmbH & Co. KG	01 Dec 2014
Uterine Cervical Dysplasia	Phase 3	Netherlands	Meda Pharma GmbH & Co. KG	01 Dec 2014
Hutchinson's Melanotic Freckle	Phase 3	France	Meda Pharma GmbH & Co. KG	01 Dec 2012
Lentigo maligna melanoma	Phase 3	France	Meda Pharma GmbH & Co. KG	01 Dec 2012
Scleroderma, Localized	Phase 3	Canada	3M Co.	01 Nov 2005
Carcinoma in Situ	Phase 2	United States	Telormedix SA	01 Feb 2013
Carcinoma in situ of bladder	Phase 2	United States	Telormedix SA	01 Feb 2013
Non-Muscle Invasive Bladder Neoplasms	Phase 2	United States	Telormedix SA	01 Feb 2013
Port-Wine Stain	Phase 2	United States	Graceway Pharmaceuticals LLC	01 Oct 2008
Capillary Hemangioma	Phase 2	Canada	Graceway Pharmaceuticals LLC	01 Mar 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04883645 (Pubmed \| Front Immunol)	Early Phase 1	Squamous cell carcinoma of the oral cavity Neoadjuvant	-	Imiquimod	hmgvtprhmx(ovcgzijxqf) = grades 1-3 xvouszkaek (jkbskevttt ) View more	Positive	27 Jan 2025
NCT01861535 \| EUCTR2012-002052-17-AT (PITVIN, ESGO2024) Manual	Phase 3	Squamous Intraepithelial Lesions	38	Imiquimod	izhhvhtass(gssjyojbbn) = The immune microenvironment of complete responders to imiquimod show a coordinated influx of CD14+ inflammatory myeloid cells and type 1 CD4+ and CD3+CD8+ T cells, both in and between epithelial and stromal compartments. The persistent lesions did not display such a coordinated immune response. Importantly, recurrent vHSIL are able to respond to imiquimod in a comparable manner to primary vHSIL when a pre-existent coordinated immune infiltrate is present. hfyqyuinsr (lhlhqjohhn )	Positive	10 Mar 2024
EADV2023	Phase 3	Hutchinson's Melanotic Freckle Neoadjuvant	283	Imiquimod	vrprwtbvqa(perfkywspn) = axlpuufjzx eubueojzwu (wwqulwskgz ) View more	Positive	11 Oct 2023
EADV2023	Phase 3	Hutchinson's Melanotic Freckle Neoadjuvant	283	Placebo	vrprwtbvqa(perfkywspn) = hovwutckmo eubueojzwu (wwqulwskgz ) View more	Positive	11 Oct 2023
ESGO2023	Not Applicable	Precancerous Conditions human papillomavirus (HPV) infection	-	Imiquimod 5%	yqgvdnckyd(ybukffiuqt) = sfcnltnucj jwoyfopygh (cmhvdbvlex )	-	27 Sep 2023
ESGO2023	Not Applicable		-	imiquimod	yqgvdnckyd(ybukffiuqt) = xpmxylsngp jwoyfopygh (cmhvdbvlex )	-	27 Sep 2023
2178 (SGO2023)	Not Applicable	Vulvar intraepithelial neoplasia	264	Imiquimod	xyeifxzthf(okwwgzzjhm) = nveclruokl mpattkyddf (idxywtezin ) View more	Positive	01 Sep 2023
WCD2023	Not Applicable	Basal Cell Carcinoma \| Actinic Keratosis	66	Topical Imiquimod	klxtkmkucv(wktyoyibrl) = ehtenupagf qkkwtrmttw (slhvwbpopk ) View more	-	05 Jul 2023
EADV2023	Not Applicable	Basal Cell Carcinoma \| Actinic Keratosis	-	Topical Imiquimod	ciarphmjic(oqffndevdf) = erythema, scales, and crusts, itching, or pain. No systemic adverse events were noted, particularly affecting the function of the transplanted organ fmdsuehbtx (zofippzftk )	-	18 May 2023
AAD2023	Not Applicable	Actinic Keratosis	17	5-FU 5% and imiquimod 5% creams	dnlgfecqcr(nzrpeugwju) = mqbdqiipcc kgqyrztgoz (ivkrhlqvqf )	-	17 Mar 2023
NCT02135419 (ANCHOR, CTgov)	Phase 3	Human Papillomavirus Infection \| Squamous Intraepithelial Lesions \| HIV Infections ... View more	4,446	infrared photocoagulation therapy+imiquimod+Fluorouracil (Arm I (Treatment))	ncchpevrlq = ycqxrgmtde mtrvhbyroz (redzpiowlw, jeufvtnrry - nsvvlbkizu) View more	-	02 Dec 2022
NCT02135419 (ANCHOR, CTgov)	Phase 3		4,446	clinical observation (Arm II (Active Monitoring) (Closed Since SEP2021))	ncchpevrlq = bekidudkoi mtrvhbyroz (redzpiowlw, hexmmmlytl - mvmmlehvge) View more	-	02 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis